Fundraising

For Fundraising enquires please contact Anna on 020 7487 3892, email [email protected] or write to us at

120 New Cavendish Street
London
W1W 6XX

Latest

The STEADY-PD Trial Results

The results of the Phase lll STEADY-PD clinical trial have now been published.
Further Support for the 'Repurposed' Simvastatin

Statins are a well characterised class of medication that are used to lower cholesterol levels in the body. Evidence strongly suggests certain statins have been for use as a potential treatment for Parkinson's, this particularly applies to a statin called simvastatin
3P: Post Doc Seminar - Membrane Trafficking in Parkinson's

Please join: Dorien Roosen, former postdoc with the NIH and Leibniz Forschüngsinstitut für Molekulare Pharmakologie, NIH, NIA, Laboratory of Neurogenetics; Luis Bonet-Ponce, postdoc with the NIH and Adamantios Mamais, former postdoc at NIH in this inaugural seminar
Please Support The Cure Parkinson’s Trust’s Charity Appeal on BBC Radio 4

We are delighted to announce that Paul Mayhew-Archer, co-writer of The Vicar of Dibley, will be presenting the BBC Radio 4 Appeal on 12 April (Easter Sunday) for The Cure Parkinson’s Trust. Please tune in.

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut...
Science news

Read the latest Parkinson's science and research news here.
Trials - Repurposed Drugs

Our International Linked Clinical Trials initiative (iLCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Apply for Funding
The NAC Trial - the facts
Our story
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Alpha-synuclein and Parkinson's

Science news

Read the latest Parkinson's science and research news here. Read more

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more

Our Annual Review 2019

Our Annual Review 2019 - your online publication here... Read more